This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. It is the third most common cardiovasculardisease [2]. For long lesions, Duo Extend smoothly overlaps with the Duo Hybrid to extend therapy.
In a retrospective study of older patients (≥65 years) with cardiovasculardisease who were admitted to a cardiology service, the prevalence of polypharmacy (five or more medications) was 95% and 69% for hyper-polypharmacy (≥10 medications), far exceeding that observed in the general population; 77.5% 2021;374:n1493.
All the patients were observed during their hospital stay for postprocedure in-hospital morbidity (pump failure, contrast-induced nephropathy, major bleeding, cerebrovascular accident/stroke, access site complications or stentthrombosis) and mortality. The mean BMI was 27.48±4.93
Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovasculardisease (CVD). The primary non-inferiority endpoint was MACCE (a composite of cardiac death, MI, ischaemic stroke, stentthrombosis, or target vessel revascularisation).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content